Martingale Asset Management L P Decreases Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Martingale Asset Management L P cut its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 28.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,985 shares of the specialty pharmaceutical company’s stock after selling 1,584 shares during the period. Martingale Asset Management L P’s holdings in Jazz Pharmaceuticals were worth $491,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. IFP Advisors Inc purchased a new stake in shares of Jazz Pharmaceuticals during the 4th quarter valued at about $25,000. Quadrant Capital Group LLC lifted its position in Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after purchasing an additional 101 shares during the period. CoreFirst Bank & Trust bought a new position in Jazz Pharmaceuticals during the fourth quarter valued at approximately $28,000. Allianz SE purchased a new stake in Jazz Pharmaceuticals in the fourth quarter worth approximately $29,000. Finally, Jones Financial Companies Lllp grew its position in Jazz Pharmaceuticals by 75.1% in the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock worth $37,000 after purchasing an additional 130 shares during the period. 89.14% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Morgan Stanley reaffirmed an “overweight” rating and issued a $183.00 price objective (up previously from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 7th. Truist Financial boosted their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research note on Thursday, March 6th. UBS Group raised shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $145.00 to $179.00 in a report on Friday, March 7th. Royal Bank of Canada cut their target price on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a research report on Wednesday, February 26th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $210.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday. One investment analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $187.71.

Jazz Pharmaceuticals Price Performance

Shares of Jazz Pharmaceuticals stock opened at $100.50 on Monday. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 52 week low of $95.49 and a 52 week high of $148.06. The stock’s 50-day simple moving average is $129.67 and its 200-day simple moving average is $122.77. The company has a market capitalization of $6.10 billion, a price-to-earnings ratio of 14.15, a PEG ratio of 1.04 and a beta of 0.42.

Insiders Place Their Bets

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the firm’s stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $123.75, for a total transaction of $185,625.00. Following the completion of the transaction, the chief executive officer now directly owns 440,307 shares of the company’s stock, valued at approximately $54,487,991.25. This trade represents a 0.34 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Patricia Carr sold 4,813 shares of the business’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $144.42, for a total transaction of $695,093.46. Following the completion of the sale, the chief accounting officer now owns 8,237 shares in the company, valued at approximately $1,189,587.54. The trade was a 36.88 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 28,736 shares of company stock worth $4,023,305 in the last three months. 4.20% of the stock is owned by company insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.